4503 Astellas Pharma explanation
- Prime Market
- TOPIX Core30
- Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical merge.
- Japan’s third largest pharmaceutical company by sales after Takeda and Otsuka Pharmaceutical
- Strengths in pharmaceuticals in oncology, immunology, renal disease, neurology, and other fields
- Mainstay prostate cancer treatment Ixtanzi (patent expires in 2027)
- New drug Fezolinatant, a treatment for vasomotor neurological symptoms during menopause
- New drug Padoseb (a treatment for urothelial carcinoma)
- Immunosuppressant Prograf (Prograf) widely used to reduce rejection after organ transplantation
- Active in open innovation
- Translated with DeepL.com (free version)
Fiscal period
Mar.
4503 Astellas Pharma Sales/Profit
Fiscal year ending March 2024
Sales：1603.6 billion yen（＋5.6%）
Operating income：25.5 billion yen（△80.8%）
Ordinary profit：24,9 billion yen（△81.1%）
